Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Smitha Udagani"'
Autor:
Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, Neesha C. Dhani, Waldo Jimenez, Stephen Welch, Helen MacKay, Josee-Lyne Ethier, Lucy Gilbert, Xuan Li, Angela Rodriguez, Lucy Chan, Valerie Bowering, Blaise Clarke, Tong Zhang, Ian King, Gregory Downs, Tracy Stockley, Lisa Wang, Smitha Udagani, Amit M. Oza, Stephanie Lheureux
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
Treatment options in patients with recurrent endometrial carcinoma (EC) are limited and response rates to chemotherapy are poor. Here the authors report the results of a phase II trial of niraparib (PARP inhibitor) monotherapy or in combination with
Externí odkaz:
https://doaj.org/article/996af268f73e4c3ab512d6bbc02ef4fa
Autor:
Andrea E. Wahner Hendrickson, Gina Mantia-Smaldone, Jaime Rodriguez-Canales, Amit M. Oza, Mihaela C. Cristea, Stephanie Lheureux, Charles A. Kunos, Suzanne Jenkins, Valerie Bowering, Eric Chen, Gini F. Fleming, Katherine Karakasis, Stephen Welch, Jeff Bruce, Tracy Stockley, Michael Tracy, Neesha C. Dhani, Lisa Wang, Smitha Udagani, Prisni Rath, Qian Tan, Johanne I Weberpals, Susan Ellard, Alexander B. Olawaiye, Swati Garg, Trevor J. Pugh, Gemma N Jones, Michael Cabanero
Publikováno v:
Lancet (London, England). 397(10271)
Summary Background The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have shown preclinical synergy and promising activity in early phase clinical trials. We aimed to determine the efficacy of this combination in patients with ovarian cancer. M
Autor:
Swati Garg, Lucy Chan, Nairi Tchrakian, Xuan Li, Neesha C. Dhani, Lisa Wang, Smitha Udagani, Amit M. Oza, Helen Mackay, Josee-Lyne Ethier, Tracy Stockley, Blaise A. Clarke, Stephen Welch, Valerie Bowering, Angela Rodriguez, Waldo Jimenez, Stephanie Lheureux, Ainhoa Madariaga, Lucy Gilbert
Publikováno v:
Journal of Clinical Oncology. 39:5574-5574
5574 Background: Treatment options in recurrent endometrial carcinoma (EC) are limited. Endometrioid EC shows alterations in PTEN, a possible biomarker of response to PARP inhibitors (PARPi). Similarly, homologous recombination deficiency (HRd), a bi
Autor:
Valentin Sotov, Mihaela C. Cristea, Amit M. Oza, Hal W. Hirte, Stephanie Lheureux, Neesha C. Dhani, Smitha Udagani, Lainie P. Martin, Marcus O. Butler, Blaise Clarke, Howard Streicher, Nhu-An Pham, Johanne I Weberpals, Patricia Shaw, Gini F. Fleming, Daliah Tsoref, Katherine Karakasis, Helen Mackay, Prafull Ghatage, Anna V. Tinker, Stephen Welch, Katia Tonkin, Vinicius Motta, Lisa Wang, Suzanne Kamel-Reid
Importance Based on evidence of human papillomavirus (HPV)–induced immune evasion, immunotherapy may be an attractive strategy in cervical cancer. Ipilimumab is a fully humanized monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a9dcf924aa75649e1bfc4ce332e694a
https://europepmc.org/articles/PMC6145732/
https://europepmc.org/articles/PMC6145732/
Autor:
Ellen Nong Wei, Amit M. Oza, Annette E. Hay, Chantale Blattler, Lisa Wang, Zhihua Li, Smitha Udagani, Christopher P. Venner, Helen X. Chen, Nizar J. Bahlis, Olena Kis, Christine Tran, Trevor J. Pugh, Signy Chow, Suzanne Trudel
Publikováno v:
Blood. 128:4526-4526
Activating mutations of the MAPK pathway are reported in over half of myeloma tumors. Experience with MEK inhibitors in solid tumors suggest that although tumors harboring BRAF or RAS mutations are more likely to respond, response rates are low and d
Autor:
Stephanie Lheureux, Marcus O. Butler, Blaise Clarke, Mihaela C. Cristea, Lainie P. Martin, Katia Sonia Tonkin, Gini F. Fleming, Anna Tinker, Hal W. Hirte, Daliah Tsoref, Helen Mackay, Neesha C. Dhani, Prafull Ghatage, Nhu-An Pham, Vinicius Motta, Lisa Wang, Katherine Karakasis, Smitha Udagani, Howard Streicher, Amit M. Oza
Publikováno v:
Journal of Clinical Oncology. 33:3061-3061
Autor:
Anna V. Tinker, Marcus O. Butler, Gini F. Fleming, Hal W. Hirte, Katherine Karakasis, Mihaela C. Cristea, Blaise A. Clarke, Daliah Tsoref, Prafull Ghatage, Smitha Udagani, Neesha C. Dhani, Katia Tonkin, Nhu-An Pham, Amit M. Oza, Lainie P. Martin, Stephanie Lheureux, Helen Mackay, Lisa Wang, Vinicius Motta, Howard Streicher
Publikováno v:
Journal of Clinical Oncology. 32:TPS5631-TPS5631
3061 Background: Response to second-line therapy in cervical cancer (CC) is infrequent. Based on evidence of HPV-induced immune evasion, immunotherapy is an attractive strategy in CC. Ipilimumab (I...